{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T17:23:11Z","timestamp":1784568191766,"version":"3.55.0"},"reference-count":155,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2019,10,25]],"date-time":"2019-10-25T00:00:00Z","timestamp":1571961600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,10,25]],"date-time":"2019-10-25T00:00:00Z","timestamp":1571961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1007\/s40264-019-00857-8","type":"journal-article","created":{"date-parts":[[2019,10,25]],"date-time":"2019-10-25T22:45:38Z","timestamp":1572043538000},"page":"1311-1327","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Benefit-Risk Assessment of Alogliptin for the Treatment of Type 2 Diabetes Mellitus"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1574-0565","authenticated-orcid":false,"given":"Kohei","family":"Kaku","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Kisanuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari","family":"Shibata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Oohira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,25]]},"reference":[{"issue":"12","key":"857_CR1","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.2337\/dc08-1035","volume":"31","author":"RA DeFronzo","year":"2008","unstructured":"DeFronzo RA, Fleck PR, Wilson CA, Mekki Q. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study. Diabetes Care. 2008;31(12):2315\u20137.","journal-title":"Diabetes Care"},{"issue":"14","key":"857_CR2","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","volume":"369","author":"WB White","year":"2013","unstructured":"White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14):1327\u201335.","journal-title":"N Engl J Med"},{"issue":"11","key":"857_CR3","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1111\/j.1463-1326.2011.01460.x","volume":"13","author":"K Kaku","year":"2011","unstructured":"Kaku K, Itayasu T, Hiroi S, Hirayama M, Seino Y. Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label long-term extension study. Diabetes Obes Metab. 2011;13(11):1028\u201335.","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"857_CR4","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/dom.12837","volume":"19","author":"K Kaku","year":"2017","unstructured":"Kaku K, Sumino S, Katou M, Nishiyama Y, Kinugawa Y. Randomized, double-blind, phase III study to evaluate the efficacy and safety of once-daily treatment with alogliptin and metformin hydrochloride in Japanese patients with type 2 diabetes. Diabetes Obes Metab. 2017;19(3):463\u20137.","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"857_CR5","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1111\/dom.12875","volume":"19","author":"L Ji","year":"2017","unstructured":"Ji L, Li L, Kuang J, Yang T, Kim DJ, Kadir AA, et al. Efficacy and safety of fixed-dose combination therapy, alogliptin plus metformin, in Asian patients with type 2 diabetes: a phase 3 trial. Diabetes Obes Metab. 2017;19(5):754\u20138.","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"857_CR6","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1185\/03007990903156111","volume":"25","author":"RE Pratley","year":"2009","unstructured":"Pratley RE, Reusch JE, Fleck PR, Wilson CA, Mekki Q. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Curr Med Res Opin. 2009;25(10):2361\u201371.","journal-title":"Curr Med Res Opin"},{"issue":"12","key":"857_CR7","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1111\/j.1463-1326.2009.01124.x","volume":"11","author":"J Rosenstock","year":"2009","unstructured":"Rosenstock J, Rendell MS, Gross JL, Fleck PR, Wilson CA, Mekki Q. Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1C) without causing weight gain or increased hypoglycaemia. Diabetes Obes Metab. 2009;11(12):1145\u201352.","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"857_CR8","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1111\/j.1463-1326.2011.01463.x","volume":"13","author":"E Bosi","year":"2011","unstructured":"Bosi E, Ellis GC, Wilson CA, Fleck PR. Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study. Diabetes Obes Metab. 2011;13(12):1088\u201396.","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"857_CR9","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1210\/jc.2011-2243","volume":"97","author":"RA DeFronzo","year":"2012","unstructured":"DeFronzo RA, Burant CF, Fleck P, Wilson C, Mekki Q, Pratley RE. Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes. J Clin Endocrinol Metab. 2012;97(5):1615\u201322.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"857_CR10","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/1753-0407.12425","volume":"9","author":"C Pan","year":"2017","unstructured":"Pan C, Han P, Ji Q, Li C, Lu J, Yang J, et al. Efficacy and safety of alogliptin in patients with type 2 diabetes mellitus: a multicentre randomized double-blind placebo-controlled phase 3 study in mainland China, Taiwan, and Hong Kong. J Diabetes. 2017;9(4):386\u201395.","journal-title":"J Diabetes."},{"issue":"11","key":"857_CR11","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1111\/j.1532-5415.2009.02484.x","volume":"57","author":"RE Pratley","year":"2009","unstructured":"Pratley RE, McCall T, Fleck PR, Wilson CA, Mekki Q. Alogliptin use in elderly people: a pooled analysis from phase 2 and 3 studies. J Am Geriatr Soc. 2009;57(11):2011\u20139.","journal-title":"J Am Geriatr Soc"},{"issue":"9","key":"857_CR12","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1185\/03007995.2011.599371","volume":"27","author":"Y Seino","year":"2011","unstructured":"Seino Y, Fujita T, Hiroi S, Hirayama M, Kaku K. Efficacy and safety of alogliptin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, dose-ranging comparison with placebo, followed by a long-term extension study. Curr Med Res Opin. 2011;27(9):1781\u201392.","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"857_CR13","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1742-1241.2008.01933.x","volume":"63","author":"MA Nauck","year":"2009","unstructured":"Nauck MA, Ellis GC, Fleck PR, Wilson CA, Mekki Q. Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study. Int J Clin Pract. 2009;63(1):46\u201355.","journal-title":"Int J Clin Pract"},{"issue":"2","key":"857_CR14","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1463-1326.2008.01016.x","volume":"11","author":"RE Pratley","year":"2009","unstructured":"Pratley RE, Kipnes MS, Fleck PR, Wilson C, Mekki Q. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy. Diabetes Obes Metab. 2009;11(2):167\u201376.","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"857_CR15","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.2337\/dc10-0159","volume":"33","author":"J Rosenstock","year":"2010","unstructured":"Rosenstock J, Inzucchi SE, Seufert J, Fleck PR, Wilson CA, Mekki Q. Initial combination therapy with alogliptin and pioglitazone in drug-naive patients with type 2 diabetes. Diabetes Care. 2010;33(11):2406\u20138.","journal-title":"Diabetes Care"},{"issue":"Suppl 3","key":"857_CR16","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1185\/03007995.2011.614936","volume":"27","author":"Y Seino","year":"2011","unstructured":"Seino Y, Fujita T, Hiroi S, Hirayama M, Kaku K. Alogliptin plus voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension. Curr Med Res Opin. 2011;27(Suppl 3):21\u20139.","journal-title":"Curr Med Res Opin"},{"issue":"12","key":"857_CR17","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/dom.12377","volume":"16","author":"S Del Prato","year":"2014","unstructured":"Del Prato S, Camisasca R, Wilson C, Fleck P. Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2-year study. Diabetes Obes Metab. 2014;16(12):1239\u201346.","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"857_CR18","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/dom.12258","volume":"16","author":"RE Pratley","year":"2014","unstructured":"Pratley RE, Fleck P, Wilson C. Efficacy and safety of initial combination therapy with alogliptin plus metformin versus either as monotherapy in drug-naive patients with type 2 diabetes: a randomized, double-blind, 6-month study. Diabetes Obes Metab. 2014;16(7):613\u201321.","journal-title":"Diabetes Obes Metab"},{"issue":"15","key":"857_CR19","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1517\/14656566.2014.956722","volume":"15","author":"K Kaku","year":"2014","unstructured":"Kaku K, Mori M, Kanoo T, Katou M, Seino Y. Efficacy and safety of alogliptin added to insulin in Japanese patients with type 2 diabetes: a randomized, double-blind, 12-week, placebo-controlled trial followed by an open-label, long-term extension phase. Expert Opin Pharmacother. 2014;15(15):2121\u201330.","journal-title":"Expert Opin Pharmacother"},{"issue":"5","key":"857_CR20","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1507\/endocrj.EJ13-0466","volume":"61","author":"M Takahara","year":"2014","unstructured":"Takahara M, Shiraiwa T, Katakami N, Kaneto H, Matsuoka TA, Shimomura I. Efficacy of adding once- and thrice-daily voglibose in Japanese type 2 diabetic patients treated with alogliptin. Endocr J. 2014;61(5):447\u201356.","journal-title":"Endocr J"},{"issue":"4","key":"857_CR21","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1530\/EJE-13-0639","volume":"170","author":"DH Van Raalte","year":"2014","unstructured":"Van Raalte DH, van Genugten RE, Eliasson B, Moller-Goede DL, Mari A, Tura A, et al. The effect of alogliptin and pioglitazone combination therapy on various aspects of beta-cell function in patients with recent-onset type 2 diabetes. Eur J Endocrinol. 2014;170(4):565\u201374.","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"857_CR22","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1161\/HYPERTENSIONAHA.116.07797","volume":"68","author":"WB White","year":"2016","unstructured":"White WB, Wilson CA, Bakris GL, Bergenstal RM, Cannon CP, Cushman WC, et al. Angiotensin-converting enzyme inhibitor use and major cardiovascular outcomes in type 2 diabetes mellitus treated with the dipeptidyl peptidase 4 inhibitor alogliptin. Hypertension. 2016;68(3):606\u201313.","journal-title":"Hypertension"},{"issue":"9","key":"857_CR23","doi-asserted-by":"crossref","first-page":"e004760","DOI":"10.1136\/bmjopen-2013-004760","volume":"4","author":"N Inagaki","year":"2014","unstructured":"Inagaki N, Ueki K, Tanizawa Y, Watada H, Nakamura J, Yamada Y, et al. Protocol for a large-scale prospective observational study with alogliptin in patients with type 2 diabetes: J-BRAND Registry. BMJ Open. 2014;4(9):e004760.","journal-title":"BMJ Open"},{"issue":"9","key":"857_CR24","doi-asserted-by":"crossref","first-page":"802","DOI":"10.14740\/jocmr3118w","volume":"9","author":"Kohzo Takebayashi","year":"2017","unstructured":"Takebayashi K, Suzuki T, Naruse R, Hara K, Suetsugu M, Tsuchiya T, et al. Long-term effect of alogliptin on glycemic control in Japanese patients with type 2 diabetes: a 3.5-year observational study. J Clin Med Res. 2017;9(9):802\u20138.","journal-title":"Journal of Clinical Medicine Research"},{"issue":"2","key":"857_CR25","doi-asserted-by":"crossref","first-page":"130","DOI":"10.14740\/jocmr2418w","volume":"8","author":"H Takeda","year":"2016","unstructured":"Takeda H, Sasai N, Ito S, Obana M, Takuma T, Takai M, et al. Efficacy and safety of alogliptin in patients with type 2 diabetes: analysis of the ATTAK-J study. J Clin Med Res. 2016;8(2):130\u201340.","journal-title":"J Clin Med Res."},{"key":"857_CR26","unstructured":"European Medicines Agency. Vipidia (alogliptin): EU summary of product characteristics. 2014. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002182\/WC500152271.pdf . Accessed 28 Mar 2019."},{"key":"857_CR27","unstructured":"Takeda Pharmaceuticals America Inc. Nesina (alogliptin), prescribing information. 2013. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/022271s000lbl.pdf . Accessed 28 Mar 2019."},{"key":"857_CR28","unstructured":"Pharmaceuticals and Medical Devices Agency. Pharmaceuticals and Medical Devices Agency approved labels: Nesina\u00ae label https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/400256_3969012F1025_1_18 . Accessed 28 Mar 2019."},{"key":"857_CR29","unstructured":"European Medicines Agency. Vipdomet (alogliptin\/metformin HCl): EU summary of product characteristics. 2014. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002654\/WC500152141.pdf . Accessed 28 Mar 2019."},{"key":"857_CR30","unstructured":"Takeda Pharmaceuticals America Inc. Kazano (alogliptin and metformin HCl), prescribing information. 2013. https:\/\/general.takedapharm.com\/KAZANOPI . Accessed 28 Mar 2019."},{"key":"857_CR31","unstructured":"Takeda Pharmaceuticals America Inc. Oseni (alogliptin and pioglitazone), prescribing information. 2013. https:\/\/general.takedapharm.com\/OSENIPI Accessed 28 Mar 2019."},{"key":"857_CR32","unstructured":"Pharmaceuticals and Medical Devices Agency. Pharmaceuticals and Medical Devices Agency approved labels: Liovel\u00ae label. https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/400256_3969103F1024_1_16 . Accessed 28 Mar 2019."},{"key":"857_CR33","unstructured":"Pharmaceuticals and Medical Devices Agency. Pharmaceuticals and Medical Devices Agency: Inisync\u00ae label. https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/400256_3969105F1023_1_05 . Accessed 28 Mar 2019."},{"key":"857_CR34","unstructured":"European Medicines Agency. Incresync (alogliptin\/pioglitazone): EU summary of product characteristics. 2014. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002178\/WC500152197.pdf . Accessed 28 Mar 2019."},{"issue":"3","key":"857_CR35","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.clinthera.2008.03.004","volume":"30","author":"P Covington","year":"2008","unstructured":"Covington P, Christopher R, Davenport M, Fleck P, Mekki QA, Wann ER, et al. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes. Clin Ther. 2008;30(3):499\u2013512.","journal-title":"Clin Ther"},{"key":"857_CR36","unstructured":"European Medicines Agency. Vipidia: Committee for Medicinal Products for human use (CHMP). 2013. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/002182\/WC500152273.pdf . Accessed 28 Mar 2019."},{"issue":"1","key":"857_CR37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40262-014-0198-2","volume":"54","author":"AJ Scheen","year":"2015","unstructured":"Scheen AJ. Pharmacokinetics and clinical use of incretin-based therapies in patients with chronic kidney disease and type 2 diabetes. Clin Pharmacokinet. 2015;54(1):1\u201321.","journal-title":"Clin Pharmacokinet"},{"key":"857_CR38","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.2337\/dci18-0007","volume":"41","author":"American Diabetes Association","year":"2018","unstructured":"American Diabetes Association. Standards of medical care in diabetes 2018. Diabetes Care. 2018;41:S1\u2013159.","journal-title":"Diabetes Care"},{"issue":"1","key":"857_CR39","doi-asserted-by":"crossref","first-page":"140","DOI":"10.2337\/dc14-2441","volume":"38","author":"SE Inzucchi","year":"2015","unstructured":"Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38(1):140\u20139.","journal-title":"Diabetes Care"},{"issue":"9","key":"857_CR40","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1007\/s00125-017-4336-x","volume":"60","author":"E Sanchez-Rangel","year":"2017","unstructured":"Sanchez-Rangel E, Inzucchi SE. Metformin: clinical use in type 2 diabetes. Diabetologia. 2017;60(9):1586\u201393.","journal-title":"Diabetologia"},{"key":"857_CR41","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3389\/fendo.2017.00006","volume":"8","author":"A Chaudhury","year":"2017","unstructured":"Chaudhury A, Duvoor C, Reddy Dendi VS, Kraleti S, Chada A, Ravilla R, et al. Clinical review of antidiabetic drugs: implications for type 2 diabetes mellitus management. Front Endocrinol. 2017;8:6.","journal-title":"Front Endocrinol."},{"issue":"6","key":"857_CR42","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.2337\/dc12-1235","volume":"36","author":"K Kodama","year":"2013","unstructured":"Kodama K, Tojjar D, Yamada S, Toda K, Patel CJ, Butte AJ. Ethnic differences in the relationship between insulin sensitivity and insulin response: a systematic review and meta-analysis. Diabetes Care. 2013;36(6):1789\u201396.","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"857_CR43","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/jdi.12490","volume":"7","author":"Y Seino","year":"2016","unstructured":"Seino Y, Kuwata H, Yabe D. Incretin-based drugs for type 2 diabetes: focus on East Asian perspectives. J Diabetes Investig. 2016;7(Suppl 1):102\u20139.","journal-title":"J Diabetes Investig."},{"issue":"3","key":"857_CR44","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41588-018-0332-4","volume":"51","author":"K Suzuki","year":"2019","unstructured":"Suzuki K, Akiyama M, Ishigaki K, Kanai M, Hosoe J, Shojima N, et al. Identification of 28 new susceptibility loci for type 2 diabetes in the Japanese population. Nat Genet. 2019;51(3):379\u201386.","journal-title":"Nat Genet"},{"issue":"3","key":"857_CR45","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/jdi.12810","volume":"9","author":"M Haneda","year":"2018","unstructured":"Haneda M, Noda M, Origasa H, Noto H, Yabe D, Fujita Y, et al. Japanese clinical practice guideline for diabetes 2016. J Diabetes Investig. 2018;9(3):657\u201397.","journal-title":"J Diabetes Investig."},{"issue":"3","key":"857_CR46","doi-asserted-by":"crossref","first-page":"e025806","DOI":"10.1136\/bmjopen-2018-025806","volume":"9","author":"R Nishimura","year":"2019","unstructured":"Nishimura R, Kato H, Kisanuki K, Oh A, Hiroi S, Onishi Y, et al. Treatment patterns, persistence and adherence rates in patients with type 2 diabetes mellitus in Japan: a claims-based cohort study. BMJ Open. 2019;9(3):e025806.","journal-title":"BMJ Open"},{"issue":"2","key":"857_CR47","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/jdi.12567","volume":"8","author":"M Tanabe","year":"2017","unstructured":"Tanabe M, Motonaga R, Terawaki Y, Nomiyama T, Yanase T. Prescription of oral hypoglycemic agents for patients with type 2 diabetes mellitus: a retrospective cohort study using a Japanese hospital database. J Diabetes Investig. 2017;8(2):227\u201334.","journal-title":"J Diabetes Investig."},{"issue":"4","key":"857_CR48","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1007\/s00125-012-2827-3","volume":"56","author":"YG Kim","year":"2013","unstructured":"Kim YG, Hahn S, Oh TJ, Kwak SH, Park KS, Cho YM. Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis. Diabetologia. 2013;56(4):696\u2013708.","journal-title":"Diabetologia"},{"issue":"4","key":"857_CR49","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1080\/14728214.2016.1257608","volume":"21","author":"A Cahn","year":"2016","unstructured":"Cahn A, Cernea S, Raz I. An update on DPP-4 inhibitors in the management of type 2 diabetes. Expert Opin Emerg Drugs. 2016;21(4):409\u201319.","journal-title":"Expert Opin Emerg Drugs."},{"issue":"2","key":"857_CR50","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2337\/diaclin.26.2.77","volume":"26","author":"MJ Fowler","year":"2008","unstructured":"Fowler MJ. Microvascular and macrovascular complications of diabetes. Clin Diabetes. 2008;26(2):77\u201382.","journal-title":"Clin Diabetes."},{"issue":"4","key":"857_CR51","doi-asserted-by":"crossref","first-page":"120","DOI":"10.4239\/wjd.v8.i4.120","volume":"8","author":"A Trikkalinou","year":"2017","unstructured":"Trikkalinou A, Papazafiropoulou AK, Melidonis A. Type 2 diabetes and quality of life. World J Diabetes. 2017;8(4):120\u20139.","journal-title":"World J Diabetes."},{"key":"857_CR52","unstructured":"World Health Organisation. Diabetes factsheet. 2017. http:\/\/www.who.int\/news-room\/fact-sheets\/detail\/diabetes . Accessed 28 Mar 2019."},{"issue":"5","key":"857_CR53","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/jdi.12333","volume":"6","author":"H Charvat","year":"2015","unstructured":"Charvat H, Goto A, Goto M, Inoue M, Heianza Y, Arase Y, et al. Impact of population aging on trends in diabetes prevalence: a meta-regression analysis of 160,000 Japanese adults. J Diabetes Investig. 2015;6(5):533\u201342.","journal-title":"J Diabetes Investig."},{"issue":"2","key":"857_CR54","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nrendo.2017.151","volume":"14","author":"Y Zheng","year":"2018","unstructured":"Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2018;14(2):88\u201398.","journal-title":"Nat Rev Endocrinol."},{"key":"857_CR55","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/nyas.12098","volume":"1281","author":"RC Ma","year":"2013","unstructured":"Ma RC, Chan JC. Type 2 diabetes in East Asians: similarities and differences with populations in Europe and the United States. Ann N Y Acad Sci. 2013;1281:64\u201391.","journal-title":"Ann N Y Acad Sci"},{"key":"857_CR56","unstructured":"World Health Organisation. Global report on diabetes. 2016. http:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/204871\/9789241565257_eng.pdf;jsessionid=57E375117D877275E79C2D9581F6E2B9?sequence=1 . Accessed 28 Mar 2019."},{"issue":"2","key":"857_CR57","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s13300-013-0034-y","volume":"4","author":"LE Garcia-Perez","year":"2013","unstructured":"Garcia-Perez LE, Alvarez M, Dilla T, Gil-Guillen V, Orozco-Beltran D. Adherence to therapies in patients with type 2 diabetes. Diabetes Ther. 2013;4(2):175\u201394.","journal-title":"Diabetes Ther."},{"key":"857_CR58","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2147\/DMSO.S38753","volume":"7","author":"BK Irons","year":"2014","unstructured":"Irons BK, Minze MG. Drug treatment of type 2 diabetes mellitus in patients for whom metformin is contraindicated. Diabetes Metab Syndr Obes. 2014;7:15\u201324.","journal-title":"Diabetes Metab Syndr Obes."},{"issue":"10","key":"857_CR59","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1021\/jm070104l","volume":"50","author":"J Feng","year":"2007","unstructured":"Feng J, Zhang Z, Wallace MB, Stafford JA, Kaldor SW, Kassel DB, et al. Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. J Med Chem. 2007;50(10):2297\u2013300.","journal-title":"J Med Chem"},{"issue":"1\u20133","key":"857_CR60","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.ejphar.2008.04.047","volume":"589","author":"B Lee","year":"2008","unstructured":"Lee B, Shi L, Kassel DB, Asakawa T, Takeuchi K, Christopher RJ. Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys. Eur J Pharmacol. 2008;589(1\u20133):306\u201314.","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"857_CR61","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/nchembio.2229","volume":"13","author":"MC Okondo","year":"2017","unstructured":"Okondo MC, Johnson DC, Sridharan R, Go EB, Chui AJ, Wang MS, et al. DPP8\/9 inhibition induces pro-caspase-1-dependent monocyte and macrophage pyroptosis. Nat Chem Biol. 2017;13(1):46\u201353.","journal-title":"Nat Chem Biol"},{"issue":"1","key":"857_CR62","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.clinthera.2006.01.015","volume":"28","author":"AJ Bergman","year":"2006","unstructured":"Bergman AJ, Stevens C, Zhou Y, Yi B, Laethem M, De Smet M, et al. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers. Clin Ther. 2006;28(1):55\u201372.","journal-title":"Clin Ther"},{"issue":"1","key":"857_CR63","doi-asserted-by":"crossref","first-page":"46","DOI":"10.5414\/CPP48046","volume":"48","author":"A Karim","year":"2010","unstructured":"Karim A, Covington P, Christopher R, Davenport M, Fleck P, Li X, et al. Pharmacokinetics of alogliptin when administered with food, metformin, or cimetidine: a two-phase, crossover study in healthy subjects. Int J Clin Pharmacol Ther. 2010;48(1):46\u201358.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"10","key":"857_CR64","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1177\/0091270009338938","volume":"49","author":"A Karim","year":"2009","unstructured":"Karim A, Laurent A, Munsaka M, Wann E, Fleck P, Mekki Q. Coadministration of pioglitazone or glyburide and alogliptin: pharmacokinetic drug interaction assessment in healthy participants. J Clin Pharmacol. 2009;49(10):1210\u20139.","journal-title":"J Clin Pharmacol"},{"issue":"10","key":"857_CR65","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/1440-1681.12455","volume":"42","author":"XW Chen","year":"2015","unstructured":"Chen XW, He ZX, Zhou ZW, Yang T, Zhang X, Yang YX, et al. Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus. Clin Exp Pharmacol Physiol. 2015;42(10):999\u20131024.","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"6","key":"857_CR66","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/dom.12643","volume":"18","author":"S Del Prato","year":"2016","unstructured":"Del Prato S, Fleck P, Wilson C, Chaudhari P. Comparison of alogliptin and glipizide for composite endpoint of glycated haemoglobin reduction, no hypoglycaemia and no weight gain in type 2 diabetes mellitus. Diabetes Obes Metab. 2016;18(6):623\u20137.","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"857_CR67","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s00125-011-2447-3","volume":"55","author":"B Eliasson","year":"2012","unstructured":"Eliasson B, Moller-Goede D, Eeg-Olofsson K, Wilson C, Cederholm J, Fleck P, et al. Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and\/or pioglitazone: a randomised double-blind placebo-controlled study. Diabetologia. 2012;55(4):915\u201325.","journal-title":"Diabetologia"},{"issue":"12","key":"857_CR68","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1111\/dom.12555","volume":"17","author":"K Kaku","year":"2015","unstructured":"Kaku K, Katou M, Igeta M, Ohira T, Sano H. Efficacy and safety of pioglitazone added to alogliptin in Japanese patients with type 2 diabetes mellitus: a multicentre, randomized, double-blind, parallel-group, comparative study. Diabetes Obes Metab. 2015;17(12):1198\u2013201.","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"857_CR69","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1111\/j.2040-1124.2012.00226.x","volume":"3","author":"Y Seino","year":"2012","unstructured":"Seino Y, Hiroi S, Hirayama M, Kaku K. Efficacy and safety of alogliptin added to sulfonylurea in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study. J Diabetes Investig. 2012;3(6):517\u201325.","journal-title":"J Diabetes Investig."},{"issue":"10","key":"857_CR70","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1111\/j.1463-1326.2012.01620.x","volume":"14","author":"Y Seino","year":"2012","unstructured":"Seino Y, Miyata Y, Hiroi S, Hirayama M, Kaku K. Efficacy and safety of alogliptin added to metformin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study. Diabetes Obes Metab. 2012;14(10):927\u201336.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"857_CR71","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s13300-017-0352-6","volume":"9","author":"Y Cai","year":"2018","unstructured":"Cai Y, Zeng T, Wen Z, Chen L. Ethnic differences in efficacy and safety of alogliptin: a systematic review and meta-analysis. Diabetes Ther. 2018;9(1):177\u201391.","journal-title":"Diabetes Ther."},{"key":"857_CR72","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s13098-016-0187-8","volume":"8","author":"K Fujibayashi","year":"2016","unstructured":"Fujibayashi K, Hayashi M, Yokokawa H, Naito T. Changes in antidiabetic prescription patterns and indicators of diabetic control among 200,000 patients over 13\u00a0years at a single institution in Japan. Diabetol Metab Syndr. 2016;8:72.","journal-title":"Diabetol Metab Syndr."},{"issue":"5","key":"857_CR73","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.2337\/dc13-2289","volume":"37","author":"Christian Hampp","year":"2014","unstructured":"Hampp C, Borders-Hemphill V, Moeny DG, Wysowski DK. Use of antidiabetic drugs in the U.S., 2003-2012. Diabetes Care. 2014;37(5):1367\u201374.","journal-title":"Diabetes Care"},{"key":"857_CR74","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2147\/DMSO.S120101","volume":"9","author":"V Higgins","year":"2016","unstructured":"Higgins V, Piercy J, Roughley A, Milligan G, Leith A, Siddall J, et al. Trends in medication use in patients with type 2 diabetes mellitus: a long-term view of real-world treatment between 2000 and 2015. Diabetes Metab Syndr Obes. 2016;9:371\u201380.","journal-title":"Diabetes Metab Syndr Obes."},{"issue":"5","key":"857_CR75","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/jdi.12183","volume":"5","author":"M Oishi","year":"2014","unstructured":"Oishi M, Yamazaki K, Okuguchi F, Sugimoto H, Kanatsuka A, Kashiwagi A. Changes in oral antidiabetic prescriptions and improved glycemic control during the years 2002-2011 in Japan (JDDM32). J Diabetes Investig. 2014;5(5):581\u20137.","journal-title":"J Diabetes Investig."},{"issue":"9","key":"857_CR76","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.2169\/internalmedicine.9481-17","volume":"57","author":"R Yamamoto-Honda","year":"2018","unstructured":"Yamamoto-Honda R, Takahashi Y, Mori Y, Yamashita S, Yoshida Y, Kawazu S, et al. Changes in antidiabetic drug prescription and glycemic control trends in elderly patients with type 2 diabetes mellitus from 2005-2013: an analysis of the National Center Diabetes Database (NCDD-03). Intern Med. 2018;57(9):1229\u201340.","journal-title":"Intern Med"},{"issue":"1","key":"857_CR77","doi-asserted-by":"crossref","first-page":"139","DOI":"10.2337\/dc15-0781","volume":"39","author":"T Mita","year":"2016","unstructured":"Mita T, Katakami N, Yoshii H, Onuma T, Kaneto H, Osonoi T, et al. Alogliptin, a dipeptidyl peptidase 4 inhibitor, prevents the progression of carotid atherosclerosis in patients with type 2 diabetes: the study of preventive effects of alogliptin on diabetic atherosclerosis (SPEAD-A). Diabetes Care. 2016;39(1):139\u201348.","journal-title":"Diabetes Care"},{"key":"857_CR78","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1472-6823-13-9","volume":"13","author":"A Berhan","year":"2013","unstructured":"Berhan A, Berhan Y. Efficacy of alogliptin in type 2 diabetes treatment: a meta-analysis of randomized double-blind controlled studies. BMC Endocr Disord. 2013;13:9.","journal-title":"BMC Endocr Disord."},{"issue":"2","key":"857_CR79","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s13300-017-0245-8","volume":"8","author":"S Kay","year":"2017","unstructured":"Kay S, Strickson A, Puelles J, Selby R, Benson E, Tolley K. Comparative effectiveness of adding alogliptin to metformin plus sulfonylurea with other DPP-4 inhibitors in type 2 diabetes: a systematic review and network meta-analysis. Diabetes Ther. 2017;8(2):251\u201373.","journal-title":"Diabetes Ther."},{"issue":"1","key":"857_CR80","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.diabet.2016.09.005","volume":"43","author":"MB Rehman","year":"2017","unstructured":"Rehman MB, Tudrej BV, Soustre J, Buisson M, Archambault P, Pouchain D, et al. Efficacy and safety of DPP-4 inhibitors in patients with type 2 diabetes: meta-analysis of placebo-controlled randomized clinical trials. Diabetes Metab. 2017;43(1):48\u201358.","journal-title":"Diabetes Metab."},{"key":"857_CR81","unstructured":"World Health Organisation. Adherence to long-term therapies: evidence for action. 2003. http:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/42682\/9241545992.pdf;jsessionid=6216B66E93FFFE5ADF1768F0530EE415?sequence=1 . Accessed 28 Mar 2019."},{"issue":"2","key":"857_CR82","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1080\/03007995.2016.1253553","volume":"33","author":"EM Flood","year":"2017","unstructured":"Flood EM, Bell KF, de la Cruz MC, Ginchereau-Sowell FM. Patient preferences for diabetes treatment attributes and drug classes. Curr Med Res Opin. 2017;33(2):261\u20138.","journal-title":"Curr Med Res Opin"},{"key":"857_CR83","doi-asserted-by":"crossref","first-page":"397","DOI":"10.2147\/PPA.S14477","volume":"4","author":"MD Dibonaventura","year":"2010","unstructured":"Dibonaventura MD, Wagner JS, Girman CJ, Brodovicz K, Zhang Q, Qiu Y, et al. Multinational internet-based survey of patient preference for newer oral or injectable type 2 diabetes medication. Patient Prefer Adherence. 2010;4:397\u2013406.","journal-title":"Patient Prefer Adherence."},{"issue":"6","key":"857_CR84","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1507\/endocrj.EJ18-0088","volume":"65","author":"H Goto","year":"2018","unstructured":"Goto H, Mita T, Fujitani Y, Fujimoto S, Takahashi K, Satoh H, et al. Effects of linagliptin versus voglibose on treatment-related quality of life in patients with type 2 diabetes: sub-analysis of the L-STEP study. Endocr J. 2018;65(6):657\u201368.","journal-title":"Endocr J"},{"issue":"5","key":"857_CR85","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s11606-008-0544-x","volume":"23","author":"F Pan","year":"2008","unstructured":"Pan F, Chernew ME, Fendrick AM. Impact of fixed-dose combination drugs on adherence to prescription medications. J Gen Intern Med. 2008;23(5):611\u20134.","journal-title":"J Gen Intern Med"},{"key":"857_CR86","unstructured":"International Diabetes Foundation. Global factsheet (English), IDF 8th Edition 2017. 2017. http:\/\/diabetesatlas.org\/resources\/2017-atlas.html . Accessed 28 Mar 2019."},{"issue":"8","key":"857_CR87","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.2337\/dc10-0843","volume":"33","author":"R Li","year":"2010","unstructured":"Li R, Zhang P, Barker LE, Chowdhury FM, Zhang X. Cost-effectiveness of interventions to prevent and control diabetes mellitus: a systematic review. Diabetes Care. 2010;33(8):1872\u201394.","journal-title":"Diabetes Care"},{"issue":"7","key":"857_CR88","doi-asserted-by":"crossref","first-page":"A337","DOI":"10.1016\/j.jval.2014.08.657","volume":"17","author":"M Pedrazzoli","year":"2014","unstructured":"Pedrazzoli M, Pasquini F, Minda K. Assessment of the economic value of Dpp-4 inhibitor alogliptin compared with sitagliptin, saxagliptin, and linagliptin. Value Health. 2014;17(7):A337.","journal-title":"Value Health."},{"issue":"8","key":"857_CR89","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1080\/00325481.2015.1085293","volume":"127","author":"F Lavernia","year":"2015","unstructured":"Lavernia F, Adkins SE, Shubrook JH. Use of oral combination therapy for type 2 diabetes in primary care: meeting individualized patient goals. Postgrad Med. 2015;127(8):808\u201317.","journal-title":"Postgrad Med"},{"issue":"4","key":"857_CR90","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s13300-016-0206-7","volume":"7","author":"J Gordon","year":"2016","unstructured":"Gordon J, McEwan P, Hurst M, Puelles J. The cost-effectiveness of alogliptin versus sulfonylurea as add-on therapy to metformin in patients with uncontrolled type 2 diabetes mellitus. Diabetes Ther. 2016;7(4):825\u201345.","journal-title":"Diabetes Ther."},{"issue":"1","key":"857_CR91","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12913-018-2860-0","volume":"18","author":"CS Kwon","year":"2018","unstructured":"Kwon CS, Seoane-Vazquez E, Rodriguez-Monguio R. Cost-effectiveness analysis of metformin\u2009+\u2009dipeptidyl peptidase-4 inhibitors compared to metformin\u2009+\u2009sulfonylureas for treatment of type 2 diabetes. BMC Health Serv Res. 2018;18(1):78.","journal-title":"BMC Health Serv Res."},{"issue":"11","key":"857_CR92","first-page":"909","volume":"68","author":"H Teramachi","year":"2013","unstructured":"Teramachi H, Ohta H, Tachi T, Toyoshima M, Mizui T, Goto C, et al. Pharmacoeconomic analysis of DPP-4 inhibitors. Pharmazie. 2013;68(11):909\u201315.","journal-title":"Pharmazie."},{"issue":"Suppl 1","key":"857_CR93","doi-asserted-by":"publisher","first-page":"S371","DOI":"10.1007\/s00125-016-4046-9","volume":"59","author":"M Munsaka","year":"2016","unstructured":"Munsaka M, Smith N, Lee D, Wilson C. Abstract 777 \u2013 Safety and tolerability of alogliptin in patients with type 2 diabetes: pooled analysis of 20 double-blind randomised controlled clinical studies. Diabetologia. 2016;59(Suppl 1):S371. https:\/\/doi.org\/10.1007\/s00125-016-4046-9 .","journal-title":"Diabetologia."},{"key":"857_CR94","unstructured":"Smith N, Pratley R, Wilson C, Mekki Q. A long-term, open-label extension study to investigate the long-term safety of alogliptin subjects with type 2 diabetes. Diabetologia. 2017;60(S357-8):Abstract 780."},{"key":"857_CR95","unstructured":"Takeda Pharmaceutical Company. Alogliptin global investigator brochure. Edition 15.0, 12 September 2018. Accessed."},{"issue":"1","key":"857_CR96","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13300-014-0061-3","volume":"5","author":"P Craddy","year":"2014","unstructured":"Craddy P, Palin HJ, Johnson KI. Comparative effectiveness of dipeptidylpeptidase-4 inhibitors in type 2 diabetes: a systematic review and mixed treatment comparison. Diabetes Ther. 2014;5(1):1\u201341.","journal-title":"Diabetes Ther."},{"issue":"2","key":"857_CR97","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2337\/dc10-1771","volume":"34","author":"MJ Willemen","year":"2011","unstructured":"Willemen MJ, Mantel-Teeuwisse AK, Straus SM, Meyboom RH, Egberts TC, Leufkens HG. Use of dipeptidyl peptidase-4 inhibitors and the reporting of infections: a disproportionality analysis in the World Health Organization VigiBase. Diabetes Care. 2011;34(2):369\u201374.","journal-title":"Diabetes Care"},{"issue":"13","key":"857_CR98","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1001\/archinte.161.13.1653","volume":"161","author":"CD Miller","year":"2001","unstructured":"Miller CD, Phillips LS, Ziemer DC, Gallina DL, Cook CB, El-Kebbi IM. Hypoglycemia in patients with type 2 diabetes mellitus. Arch Intern Med. 2001;161(13):1653\u20139.","journal-title":"Arch Intern Med"},{"issue":"1","key":"857_CR99","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3810\/pgm.2012.01.2525","volume":"124","author":"M Bron","year":"2012","unstructured":"Bron M, Marynchenko M, Yang H, Yu AP, Wu EQ. Hypoglycemia, treatment discontinuation, and costs in patients with type 2 diabetes mellitus on oral antidiabetic drugs. Postgrad Med. 2012;124(1):124\u201332.","journal-title":"Postgrad Med"},{"issue":"8","key":"857_CR100","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.2337\/dc09-0114","volume":"32","author":"JP Bremer","year":"2009","unstructured":"Bremer JP, Jauch-Chara K, Hallschmid M, Schmid S, Schultes B. Hypoglycemia unawareness in older compared with middle-aged patients with type 2 diabetes. Diabetes Care. 2009;32(8):1513\u20137.","journal-title":"Diabetes Care"},{"issue":"10","key":"857_CR101","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1111\/dom.12102","volume":"15","author":"J Rosenstock","year":"2013","unstructured":"Rosenstock J, Wilson C, Fleck P. Alogliptin versus glipizide monotherapy in elderly type 2 diabetes mellitus patients with mild hyperglycaemia: a prospective, double-blind, randomized, 1-year study. Diabetes Obes Metab. 2013;15(10):906\u201314.","journal-title":"Diabetes Obes Metab"},{"key":"857_CR102","doi-asserted-by":"crossref","first-page":"i2231","DOI":"10.1136\/bmj.i2231","volume":"353","author":"F Salvo","year":"2016","unstructured":"Salvo F, Moore N, Arnaud M, Robinson P, Raschi E, De Ponti F, et al. Addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia: systematic review and meta-analysis. BMJ. 2016;353:i2231.","journal-title":"BMJ"},{"issue":"6","key":"857_CR103","doi-asserted-by":"crossref","first-page":"489","DOI":"10.2165\/00002018-199920060-00003","volume":"20","author":"HC Howlett","year":"1999","unstructured":"Howlett HC, Bailey CJ. A risk-benefit assessment of metformin in type 2 diabetes mellitus. Drug Saf. 1999;20(6):489\u2013503.","journal-title":"Drug Saf"},{"key":"857_CR104","unstructured":"International Diabetes Foundation. Diabetes Atlas: Second edition 2003. 2013. https:\/\/www.idf.org\/e-library\/epidemiology-research\/diabetes-atlas\/23-atlas-2nd-edition-year.html . Accessed 28 Mar 2019."},{"issue":"12","key":"857_CR105","doi-asserted-by":"crossref","first-page":"4083","DOI":"10.2337\/dc13-0496","volume":"36","author":"H Sell","year":"2013","unstructured":"Sell H, Bluher M, Kloting N, Schlich R, Willems M, Ruppe F, et al. Adipose dipeptidyl peptidase-4 and obesity: correlation with insulin resistance and depot-specific release from adipose tissue in vivo and in vitro. Diabetes Care. 2013;36(12):4083\u201390.","journal-title":"Diabetes Care"},{"issue":"5","key":"857_CR106","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/jdi.12779","volume":"9","author":"H Kuwata","year":"2018","unstructured":"Kuwata H, Okamoto S, Seino Y, Murotani K, Tatsuoka H, Usui R, et al. Relationship between deterioration of glycated hemoglobin-lowering effects in dipeptidyl peptidase-4 inhibitor monotherapy and dietary habits: retrospective analysis of Japanese individuals with type 2 diabetes. J Diabetes Investig. 2018;9(5):1153\u20138.","journal-title":"J Diabetes Investig."},{"issue":"3","key":"857_CR107","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s11892-013-0378-8","volume":"13","author":"H Yau","year":"2013","unstructured":"Yau H, Rivera K, Lomonaco R, Cusi K. The future of thiazolidinedione therapy in the management of type 2 diabetes mellitus. Curr Diab Rep. 2013;13(3):329\u201341.","journal-title":"Curr Diab Rep."},{"issue":"9982","key":"857_CR108","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1016\/S0140-6736(14)62225-X","volume":"385","author":"F Zannad","year":"2015","unstructured":"Zannad F, Cannon CP, Cushman WC, Bakris GL, Menon V, Perez AT, et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet. 2015;385(9982):2067\u201376.","journal-title":"Lancet"},{"key":"857_CR109","unstructured":"American Diabetes Association. 2018 standards of medical care in diabetes, with notable new recommendations for people with cardiovascular disease and diabetes. 2017. http:\/\/www.diabetes.org\/newsroom\/press-releases\/2017\/american-diabetes-association-2018-release-standards-of-medical-care-in-diabetes.html . Accessed 24 July 2019."},{"key":"857_CR110","doi-asserted-by":"crossref","unstructured":"American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: Standards of medical care in diabetes-2019. Diabetes Care. 2019;42(Suppl 1):S90\u2013S102.","DOI":"10.2337\/dc19-S009"},{"issue":"8","key":"857_CR111","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1111\/bcp.13611","volume":"84","author":"A Avogaro","year":"2018","unstructured":"Avogaro A, Fadini GP. The pleiotropic cardiovascular effects of dipeptidyl peptidase-4 inhibitors. Br J Clin Pharmacol. 2018;84(8):1686\u201395.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"857_CR112","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/dom.12871","volume":"19","author":"SR Heller","year":"2017","unstructured":"Heller SR, Bergenstal RM, White WB, Kupfer S, Bakris GL, Cushman WC, et al. Relationship of glycated haemoglobin and reported hypoglycaemia to cardiovascular outcomes in patients with type 2 diabetes and recent acute coronary syndrome events: the EXAMINE trial. Diabetes Obes Metab. 2017;19(5):664\u201371.","journal-title":"Diabetes Obes Metab"},{"key":"857_CR113","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ahj.2016.01.011","volume":"175","author":"YJ Shimada","year":"2016","unstructured":"Shimada YJ, Cannon CP, Liu Y, Wilson C, Kupfer S, Menon V, et al. Ischemic cardiac outcomes and hospitalizations according to prior macrovascular disease status in patients with type 2 diabetes and recent acute coronary syndrome from the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care trial. Am Heart J. 2016;175:18\u201327.","journal-title":"Am Heart J"},{"issue":"7","key":"857_CR114","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.amjmed.2018.02.023","volume":"131","author":"WB White","year":"2018","unstructured":"White WB, Heller SR, Cannon CP, Howitt H, Khunti K, Bergenstal RM. Alogliptin in patients with type 2 diabetes receiving metformin and sulfonylurea therapies in the EXAMINE trial. Am J Med. 2018;131(7):813\u20139.e5.","journal-title":"Am J Med."},{"issue":"7","key":"857_CR115","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.2337\/dc16-0303","volume":"39","author":"WB White","year":"2016","unstructured":"White WB, Kupfer S, Zannad F, Mehta CR, Wilson CA, Lei L, et al. Cardiovascular mortality in patients with type 2 diabetes and recent acute coronary syndromes from the EXAMINE trial. Diabetes Care. 2016;39(7):1267\u201373.","journal-title":"Diabetes Care"},{"issue":"2","key":"857_CR116","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/nrcardio.2012.183","volume":"10","author":"AJ Scheen","year":"2013","unstructured":"Scheen AJ. Cardiovascular effects of gliptins. Nat Rev Cardiol. 2013;10(2):73\u201384.","journal-title":"Nat Rev Cardiol."},{"issue":"4","key":"857_CR117","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1080\/14740338.2018.1444027","volume":"17","author":"AJ Scheen","year":"2018","unstructured":"Scheen AJ. The safety of gliptins: updated data in 2018. Expert Opin Drug Saf. 2018;17(4):387\u2013405.","journal-title":"Expert Opin Drug Saf."},{"key":"857_CR118","doi-asserted-by":"crossref","first-page":"i610","DOI":"10.1136\/bmj.i610","volume":"352","author":"L Li","year":"2016","unstructured":"Li L, Li S, Deng K, Liu J, Vandvik PO, Zhao P, et al. Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies. BMJ. 2016;352:i610.","journal-title":"BMJ"},{"issue":"6","key":"857_CR119","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1002\/pds.4437","volume":"27","author":"SN Baksh","year":"2018","unstructured":"Baksh SN, McAdams-DeMarco M, Segal JB, Alexander GC. Cardiovascular safety signals with dipeptidyl peptidase-4 inhibitors: a disproportionality analysis among high-risk patients. Pharmacoepidemiol Drug Saf. 2018;27(6):660\u20137.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"5","key":"857_CR120","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.numecd.2016.02.006","volume":"26","author":"E Raschi","year":"2016","unstructured":"Raschi E, Poluzzi E, Koci A, Antonazzo IC, Marchesini G, De Ponti F. Dipeptidyl peptidase-4 inhibitors and heart failure: analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System. Nutr Metab Cardiovasc Dis. 2016;26(5):380\u20136.","journal-title":"Nutr Metab Cardiovasc Dis."},{"issue":"9","key":"857_CR121","doi-asserted-by":"crossref","first-page":"e003957","DOI":"10.1161\/CIRCHEARTFAILURE.117.003957","volume":"10","author":"YG Kim","year":"2017","unstructured":"Kim YG, Yoon D, Park S, Han SJ, Kim DJ, Lee KW, et al. Dipeptidyl peptidase-4 inhibitors and risk of heart failure in patients with type 2 diabetes mellitus: a population-based cohort study. Circ Heart Fail. 2017;10(9):e003957.","journal-title":"Circ Heart Fail."},{"issue":"1","key":"857_CR122","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12933-019-0835-z","volume":"18","author":"KJ Kim","year":"2019","unstructured":"Kim KJ, Choi J, Lee J, Bae JH, An JH, Kim HY, et al. Dipeptidyl peptidase-4 inhibitor compared with sulfonylurea in combination with metformin: cardiovascular and renal outcomes in a propensity-matched cohort study. Cardiovasc Diabetol. 2019;18(1):28.","journal-title":"Cardiovasc Diabetol."},{"issue":"3","key":"857_CR123","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.jjcc.2016.04.014","volume":"69","author":"T Nozue","year":"2017","unstructured":"Nozue T, Fukui K, Takamura T, Sozu T, Hibi K, Kishi S, et al. Effects of alogliptin on fractional flow reserve evaluated by coronary computed tomography angiography in patients with type 2 diabetes: rationale and design of the TRACT study. J Cardiol. 2017;69(3):518\u201322.","journal-title":"J Cardiol"},{"key":"857_CR124","unstructured":"European Medicines Agency. Onglyza (saxagliptin): EU summary of product characteristics. 2018. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/onglyza-epar-product-information_en.pdf . Accessed 28 Mar 2019."},{"key":"857_CR125","unstructured":"European Medicines Agency. Jalra (vildagliptin): EU summary of product characteristics. 2018. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/jalra-epar-product-information_en.pdf . Accessed 28 Mar 2019."},{"issue":"2","key":"857_CR126","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3803\/EnM.2019.34.2.106","volume":"34","author":"GS Kim","year":"2019","unstructured":"Kim GS, Park JH, Won JC. The role of glucagon-like peptide 1 receptor agonists and sodium-glucose cotransporter 2 inhibitors in reducing cardiovascular events in patients with type 2 diabetes. Endocrinol Metab (Seoul). 2019;34(2):106\u201316.","journal-title":"Endocrinol Metab (Seoul)."},{"issue":"11","key":"857_CR127","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.2337\/dc10-0482","volume":"33","author":"R Garg","year":"2010","unstructured":"Garg R, Chen W, Pendergrass M. Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis. Diabetes Care. 2010;33(11):2349\u201354.","journal-title":"Diabetes Care"},{"issue":"10","key":"857_CR128","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1111\/dme.12301","volume":"30","author":"RE Ryder","year":"2013","unstructured":"Ryder RE. The potential risks of pancreatitis and pancreatic cancer with GLP-1-based therapies are far outweighed by the proven and potential (cardiovascular) benefits. Diabet Med. 2013;30(10):1148\u201355.","journal-title":"Diabet Med"},{"key":"857_CR129","doi-asserted-by":"crossref","first-page":"g2780","DOI":"10.1136\/bmj.g2780","volume":"348","author":"JL Faillie","year":"2014","unstructured":"Faillie JL, Azoulay L, Patenaude V, Hillaire-Buys D, Suissa S. Incretin based drugs and risk of acute pancreatitis in patients with type 2 diabetes: cohort study. BMJ. 2014;348:g2780.","journal-title":"BMJ"},{"issue":"1","key":"857_CR130","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1177\/1060028015610123","volume":"50","author":"AK Nagel","year":"2016","unstructured":"Nagel AK, Ahmed-Sarwar N, Werner PM, Cipriano GC, Van Manen RP, Brown JE. Dipeptidyl peptidase-4 inhibitor-associated pancreatic carcinoma: a review of the FAERS database. Ann Pharmacother. 2016;50(1):27\u201331.","journal-title":"Ann Pharmacother"},{"key":"857_CR131","doi-asserted-by":"crossref","first-page":"i581","DOI":"10.1136\/bmj.i581","volume":"352","author":"L Azoulay","year":"2016","unstructured":"Azoulay L, Filion KB, Platt RW, Dahl M, Dormuth CR, Clemens KK, et al. Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study. BMJ. 2016;352:i581.","journal-title":"BMJ"},{"issue":"5","key":"857_CR132","doi-asserted-by":"crossref","first-page":"e3004","DOI":"10.1002\/dmrr.3004","volume":"34","author":"JA Overbeek","year":"2018","unstructured":"Overbeek JA, Bakker M, van der Heijden A, van Herk-Sukel MPP, Herings RMC, Nijpels G. Risk of dipeptidyl peptidase-4 (DPP-4) inhibitors on site-specific cancer: a systematic review and meta-analysis. Diabetes Metab Res Rev. 2018;34(5):e3004.","journal-title":"Diabetes Metab Res Rev."},{"issue":"1","key":"857_CR133","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1038\/s41598-017-19055-6","volume":"8","author":"LC Pinto","year":"2018","unstructured":"Pinto LC, Rados DV, Barkan SS, Leitao CB, Gross JL. Dipeptidyl peptidase-4 inhibitors, pancreatic cancer and acute pancreatitis: a meta-analysis with trial sequential analysis. Sci Rep. 2018;8(1):782.","journal-title":"Sci Rep."},{"issue":"1","key":"857_CR134","doi-asserted-by":"crossref","first-page":"9719","DOI":"10.1038\/s41598-018-27965-2","volume":"8","author":"DY Lee","year":"2018","unstructured":"Lee DY, Yu JH, Park S, Han K, Kim NH, Yoo HJ, et al. The influence of diabetes and antidiabetic medications on the risk of pancreatic cancer: a nationwide population-based study in Korea. Sci Rep. 2018;8(1):9719.","journal-title":"Sci Rep."},{"issue":"10","key":"857_CR135","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1001\/jamainternmed.2016.1531","volume":"176","author":"JL Faillie","year":"2016","unstructured":"Faillie JL, Yu OH, Yin H, Hillaire-Buys D, Barkun A, Azoulay L. Association of bile duct and gallbladder diseases with the use of incretin-based drugs in patients with type 2 diabetes mellitus. JAMA Intern Med. 2016;176(10):1474\u201381.","journal-title":"JAMA Intern Med."},{"issue":"2","key":"857_CR136","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/bjd.14601","volume":"175","author":"J Bene","year":"2016","unstructured":"Bene J, Moulis G, Bennani I, Auffret M, Coupe P, Babai S, et al. Bullous pemphigoid and dipeptidyl peptidase IV inhibitors: a case-noncase study in the French Pharmacovigilance Database. Br J Dermatol. 2016;175(2):296\u2013301.","journal-title":"Br J Dermatol"},{"issue":"5","key":"857_CR137","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.jid.2017.11.023","volume":"138","author":"H Ujiie","year":"2018","unstructured":"Ujiie H, Muramatsu K, Mushiroda T, Ozeki T, Miyoshi H, Iwata H, et al. HLA-DQB1*03:01 as a biomarker for genetic susceptibility to bullous pemphigoid induced by DPP-4 inhibitors. J Invest Dermatol. 2018;138(5):1201\u20134.","journal-title":"J Invest Dermatol."},{"issue":"9","key":"857_CR138","doi-asserted-by":"crossref","first-page":"e130","DOI":"10.2337\/dc18-0210","volume":"41","author":"M Arai","year":"2018","unstructured":"Arai M, Shirakawa J, Konishi H, Sagawa N, Terauchi Y. Bullous pemphigoid and dipeptidyl peptidase 4 inhibitors: a disproportionality analysis based on the Japanese adverse drug event report database. Diabetes Care. 2018;41(9):e130\u20132.","journal-title":"Diabetes Care"},{"issue":"3","key":"857_CR139","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/jcpt.12397","volume":"41","author":"M Garcia","year":"2016","unstructured":"Garcia M, Aranburu MA, Palacios-Zabalza I, Lertxundi U, Aguirre C. Dipeptidyl peptidase-IV inhibitors induced bullous pemphigoid: a case report and analysis of cases reported in the European pharmacovigilance database. J Clin Pharm Ther. 2016;41(3):368\u201370.","journal-title":"J Clin Pharm Ther"},{"issue":"10","key":"857_CR140","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1001\/jamadermatol.2018.2352","volume":"154","author":"K Kridin","year":"2018","unstructured":"Kridin K, Bergman R. Association of bullous pemphigoid with dipeptidyl-peptidase 4 inhibitors in patients with diabetes: estimating the risk of the new agents and characterizing the patients. JAMA Dermatol. 2018;154(10):1152\u20138.","journal-title":"JAMA Dermatol."},{"issue":"2","key":"857_CR141","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1001\/jamadermatol.2018.4556","volume":"155","author":"SG Lee","year":"2019","unstructured":"Lee SG, Lee HJ, Yoon MS, Kim DH. Association of dipeptidyl peptidase 4 inhibitor use with risk of bullous pemphigoid in patients with diabetes. JAMA Dermatol. 2019;155(2):172\u20137.","journal-title":"JAMA Dermatol."},{"key":"857_CR142","doi-asserted-by":"crossref","first-page":"k872","DOI":"10.1136\/bmj.k872","volume":"360","author":"D Abrahami","year":"2018","unstructured":"Abrahami D, Douros A, Yin H, Yu OHY, Renoux C, Bitton A, et al. Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study. BMJ. 2018;360:k872.","journal-title":"BMJ"},{"issue":"1\u20133","key":"857_CR143","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.regpep.2012.04.006","volume":"177","author":"GW Moran","year":"2012","unstructured":"Moran GW, O\u2019Neill C, Padfield P, McLaughlin JT. Dipeptidyl peptidase-4 expression is reduced in Crohn\u2019s disease. Regul Pept. 2012;177(1\u20133):40\u20135.","journal-title":"Regul Pept"},{"issue":"1","key":"857_CR144","doi-asserted-by":"crossref","first-page":"164","DOI":"10.2337\/diacare.28.1.164","volume":"28","author":"JL Gross","year":"2005","unstructured":"Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care. 2005;28(1):164\u201376.","journal-title":"Diabetes Care"},{"key":"857_CR145","unstructured":"International Diabetes Foundation. Care and prevention. Diabetes and the kidneys https:\/\/www.idf.org\/our-activities\/care-prevention\/diabetes-and-the-kidney.html . Accessed 28 March 2019."},{"issue":"3","key":"857_CR146","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1517\/14656566.2013.761690","volume":"14","author":"Y Fujii","year":"2013","unstructured":"Fujii Y, Abe M, Higuchi T, Mizuno M, Suzuki H, Matsumoto S, et al. The dipeptidyl peptidase-4 inhibitor alogliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis. Expert Opin Pharmacother. 2013;14(3):259\u201367.","journal-title":"Expert Opin Pharmacother"},{"issue":"1\u20132","key":"857_CR147","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1159\/000351678","volume":"123","author":"Y Nakamura","year":"2013","unstructured":"Nakamura Y, Inagaki M, Shimizu T, Fujita K, Inoue M, Gotoh H, et al. Long-term effects of alogliptin benzoate in hemodialysis patients with diabetes: a 2-year study. Nephron Clin Pract. 2013;123(1\u20132):46\u201351.","journal-title":"Nephron Clin Pract."},{"issue":"3","key":"857_CR148","doi-asserted-by":"crossref","first-page":"195","DOI":"10.2169\/internalmedicine.53.1292","volume":"53","author":"Y Sakai","year":"2014","unstructured":"Sakai Y, Suzuki A, Mugishima K, Sumi Y, Otsuka Y, Otsuka T, et al. Effects of alogliptin in chronic kidney disease patients with type 2 diabetes. Intern Med. 2014;53(3):195\u2013203.","journal-title":"Intern Med"},{"key":"857_CR149","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/psb.1609","volume":"28","author":"E Goodchild","year":"2017","unstructured":"Goodchild E, Chowdhury T. Managing diabetes in the presence of renal impairment. Prescriber. 2017;28:24\u201330.","journal-title":"Prescriber."},{"issue":"1","key":"857_CR150","first-page":"193","volume":"21","author":"NA Baig","year":"2001","unstructured":"Baig NA, Herrine SK, Rubin R. Liver disease and diabetes mellitus. Clin Lab Med. 2001;21(1):193\u2013207.","journal-title":"Clin Lab Med"},{"issue":"3","key":"857_CR151","doi-asserted-by":"crossref","first-page":"734","DOI":"10.2337\/dc06-1539","volume":"30","author":"KG Tolman","year":"2007","unstructured":"Tolman KG, Fonseca V, Dalpiaz A, Tan MH. Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. Diabetes Care. 2007;30(3):734\u201343.","journal-title":"Diabetes Care"},{"issue":"2","key":"857_CR152","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3892\/br.2016.569","volume":"4","author":"T Mashitani","year":"2016","unstructured":"Mashitani T, Noguchi R, Okura Y, Namisaki T, Mitoro A, Ishii H, et al. Efficacy of alogliptin in preventing non-alcoholic fatty liver disease progression in patients with type 2 diabetes. Biomed Rep. 2016;4(2):183\u20137.","journal-title":"Biomed Rep."},{"issue":"11","key":"857_CR153","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1007\/s40262-014-0199-1","volume":"53","author":"E Barbehenn","year":"2014","unstructured":"Barbehenn E, Almashat S, Carome M, Wolfe S. Hepatotoxicity of alogliptin. Clin Pharmacokinet. 2014;53(11):1055\u20136.","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"857_CR154","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s40262-015-0248-4","volume":"54","author":"E Raschi","year":"2015","unstructured":"Raschi E, Poluzzi E, De Ponti F. Comment on: \u201cPharmacokinetics in patients with chronic liver disease and hepatic safety of incretin-based therapies for the management of type 2 diabetes mellitus\u201d. Clin Pharmacokinet. 2015;54(4):447\u20138.","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"857_CR155","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1080\/03007995.2017.1345730","volume":"33","author":"D Ayers","year":"2017","unstructured":"Ayers D, Kanters S, Goldgrub R, Hughes M, Kato R, Kragh N. Network meta-analysis of liraglutide versus dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes in Japanese patients. Curr Med Res Opin. 2017;33(9):1653\u201361.","journal-title":"Curr Med Res Opin"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-019-00857-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40264-019-00857-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-019-00857-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,2]],"date-time":"2022-10-02T18:11:30Z","timestamp":1664734290000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40264-019-00857-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,25]]},"references-count":155,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["857"],"URL":"https:\/\/doi.org\/10.1007\/s40264-019-00857-8","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,25]]},"assertion":[{"value":"25 October 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This review was funded by Takeda Pharmaceutical Co. Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Kohei Kaku has received grants\/pending grants from Boehringer Ingelheim Japan, Mitsubishi Tanabe-Pharma, and Taisho Toyama Pharmaceutical; consulting fees\/honorarium from Sanwa Kagaku Kenkyusho; payment for lectures including services on speakers bureaus from Astellas Pharma, AstraZeneca, Boehringer Ingelheim Japan, Elli Lilly Japan, MSD, Novo Nordisk Pharma, Ono-Yakuhin, Sanwa Kagaku Kenkyusho, Taisho Toyama Pharmaceutical, and Takeda Pharmaceutical Company Limited. Koichi Kisanuki, Mari Shibata, and Takashi Oohira are employees of Takeda Pharmaceutical Company Limited.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}